

Please type a plus sign (+) inside this

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Shee

1

1

<i>Complete if Known</i>	
Application Number	10/086,417
Filing Date	March 4, 2002
First Named Inventor	Bernd Riedl et al.
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	BAYER-16P4

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS


Examiner Initials*	Cite No. ¹	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ₆
		Office	Number ⁴	Kind Code ⁵ (if known)			
		JP	54-032468		9-3-1979		
		EP	0405233A1		1-2-91		
		EP	0379015A1		8-1-90		
		EP	0381987A1		8-16-90		
		EP	0380048A2		8-1-90		
		EP	0264904A2		4-27-88		
		EP	0359148A1		3-21-90		
		EP	0233559B1		8-26-87		
		EP	0230400A2		7-29-87		

Examiner Signature	<u>CJN</u>	Date Considered	10-29-04
--------------------	------------	-----------------	----------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 8

Complete If Known

Application Number	10/086,417
Filing Date	March 4, 2002
First Named Inventor	Bernd Riedl et al.
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	BAYER-16P4

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS


Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Publication No. US 2002/0065296 A1, Publication Date: May 30, 2002, Bumas et al.	
		Publication No. US 2002/0062763 A1, Publication Date: May 30, 2003, Macholdt et al.	
		Publication No. US 2002/012831 A1, Publication Date: September 24, 2002, Widdowson et al.	
		Publication No. US 2002/0082255 a1, Publication Date: June 27, 2002, Eastwood	
		Caplus 113:106314, Abstract of JP 2022650, Silver halide color photographic material containing a cyan coupler or 2-ureido-phenol-type to improve dye developability and remove tecuo cyan dye, Neboru Mizukura et al. January 25, 1990.	
		Caplus 140:142130, Abstract of JP 2023337, Silver halide photographic material containing phenolic cyan couples a colorless cyan coupler, Toshihiko Yagi et al., January 25, 1990.	
		Caplus 87:62295, "The metabolism and toxicity of halogenated carbanilides. Biliary metabolites of 3,4,4'-trichlorocarbanilide and 3-(fluoromethyl)-4,4'-dichlorocarbanilide in the rat", Chemical Life Science, pp. 157-66, 1977.	
		Caplus 127:293717, "Optical properties of segmented oligourethane with azomethine terminal fragments", National Academy of Science of Ukraine, M. V. Kurik et al., pp. 2038-2041, 1996.	
		Caplus 127:273945, "Quantitative structure-biodegradability studies: an investigation of the MITI aromatic compound database", School of Pharmacy and Chemistry, J. C. Dearden, pp. 93-104, 1995.	
		Caplus 128:168148, "Inhibitors of coenzyme A-independent transacylase induce apoptosis in human HL-60 cells", James D. Winkler et al., J. Pharmacol. Exp. Ther. pp. 956-966, 1996.	
		Caplus 98:78152, Abstract of JP 57185219, "Antitumor benzophenone derivatives", November 15, 1982.	

Examiner Signature	<i>CM</i>	Date Considered	10-29-04
--------------------	-----------	-----------------	----------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Do not respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1448A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 8

Substitute for form 1449A/PTO			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			
(use as many sheets as necessary)			
Sheet	3	of	8
<i>DEMAILED</i>			
Complete if Known			
Application Number		10/086,417	
Filing Date		March 4, 2002	
First Named Inventor		Bernd Riedl et al.	
Group Art Unit		Unassigned	
Examiner Name		Unassigned	
Attorney Docket Number		BAYER-16P4	

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ₆
		Office ³	Number ⁴				
		EP	0102263B1		8-27-1986		
		EP	0107214A1		5-2-1984		
		WO	0047577		8-17-2000		
		WO	99/21835		5-6-1999		
		WO	99/24635		5-6-1999		
		WO	00/41698		7-20-2000		
		WO	00/42012		7-20-2000		
		WO	01/36405A1		5-25-2001		
		WO	96/13632		5-9-1996		
		WO	99/20617		4-29-1999		
		WO	96/13632		5-9-1996		
		WO	02/24635A2		3-28-2002		
		IR	26555				
		LB	6124				

Examiner Signature	CJM	Date Considered	10-29-04
-----------------------	-----	--------------------	----------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

4

Of

8

Complete If Known	
Application Number	10/086,417
Filing Date	March 4, 2002
First Named Inventor	Bern Riedl et al.
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	BAYER-16P4

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Caplus 72:79046, Abstract of CH 479557, "Tuberculostatic and cancerostatic polybasic ureas", Dr. A. Wander, October 15, 1969.	
		Caplus 125:245169, "Production of murine monoclonal antibodies against sulcofuran and flucofuran by in vitro immunization", G. A. Bonwick et al., J. Immunol. Methods, pp. 163-173, 1996.	
		Caplus 127:34137f, "Preparation of quinoline and quinazoline derivatives Inhibiting platelet-derived growth factor receptor autophosphorylation", Kazuo Kubo et al., May 16, 1997.	
		Caplus 131:58858, "Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas", Miller, Scott, July 1, 1999.	
		Caplus 131:87909y, "Inhibition of p38 kinase activity using substituted heterocyclic ureas", Jacques Dumas, July 1, 1999.	
		Caplus 131:73649b, "Preparation of pyrazolyl aryl ureas and related compounds as p38kinase inhibitor", Jacques Dumas, July 1, 1999.	
		Joseph V. Simone, "Cecil Textbook of Medicine", 20th Edition, Vol. 1, 2-3-1997, pp. 1004-1010.	
		Cesar Raposo et al., "Catalysis of Nucleophilic Addition of Pyrrolidine to 2-(5H)-Furanone through Chromenone Cleft-Type Receptors", Vol. 37, No. 38, pp. 6947-6950, 1998.	
		Jacqueline E. van Muuijwijk-Koozen et al., "Isoquinoline and Quinazoline Urea Analogues as Antagonists for the Human Adenosine A ₂ Receptor", J. Ed. Chem. 2000, 43, pp. 2227-2238, January 3, 2000.	
		Jacques Dumas et al., "1-Phenyl-5-pyrazolyl Ureas: Potent and Selective p38 Kinase Inhibitors", Bioorganic & Medicinal Chemistry Letters, pp. 2051-2054, May 2, 2000.	
		Robert W. Carling et al., "1-(3-Cyanobenxypiperidin-4-yl)-5-methyl-4-phenyl-1,3-dihydroimidazol-2-one: A Selective High-Affinity Antagonist for the Human Dopamine D ₄ Receptor with Excellent Selectivity over Ion Channels", J. Med. Chem., 1999, 42, pp. 2706-2715.	
		Abstract WO 9822103, May 28, 1998, John Philip Hodge et al.	

Examiner Signature

CM

Date Considered

10-29-04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	5	Of	8	Filing Date	March 4, 2002
				First Named Inventor	Bern Riedl et al.
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
				Attorney Docket Number	BAYER-16P4

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Abstract of DE 3305800A1, August 29, 1984, Dr. Acker Rolf-Dieter et al.	
		Abstract of EP 4931 (equivalent 4,240,820), K. Dickore et al. (1980)	
		Dumas, J. "CAS Structure," May 6, 1997, pages 1-29	
		Scott, Bill, "Substructure (Patent Families)", August 11, 1997, pages 1-19.	
		Scott, Bill, "Substructure #2", November 25, 1997, pages 1-3.	
		"Beilstein number" Collection, 28 pages (1997)	
		"Beilstein Collection", 4 pages (1997)	
		Scott, Bill, "Substructure Search", December 2, 1997, pages 1-51.	
		Substructure Search, pages 1-30. (1997)	
		Derwent World Patents Index Search, pages 20-26. (1997)	
		Abstract of EP 116,932 (1984)	
		Abstract of EP 676,395 (1995)	
		Abstract of EP 202,538 (1986)	
		Abstract of EP 16,371 (1980)	

Examiner Signature	<i>CM</i>	Date Considered	10-29-04
--------------------	-----------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



DEC 30 2002

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

6

of

8

Complete If Known

Application Number	10/086,417
Filing Date	March 4, 2002
First Named Inventor	Bernd Riedl et al.
Group Art Unit	Unassigned
Examiner Name	Unassigned

Attorney Docket Number BAYER 16P4

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	AA	A "Notice of References Cited" from the USPTO for U.S. application 08/995,749.
	AB	A "Notice of References Cited" from the USPTO for U.S. application 09/083,399.
	AC AND AD	A "Notice of References Cited" from the USPTO for U.S. application 09/425,228.
	AE	A "Notice of References Cited" from the USPTO for U.S. application 09/425,229.
	AF	A "Notice of References Cited" from the USPTO for U.S. application 09/458,015.
	AG	A "Notice of References Cited" from the USPTO for U.S. application 09/472,292.
	AH	A "Notice of References Cited" from the USPTO for U.S. application 09/472,232.
	AI	A "Notice of References Cited" from the USPTO for U.S. application 09/773,604.
	AJ	A "Notice of References Cited" from the USPTO for U.S. application 09/773,659.
	AK	A "Notice of References Cited" from the USPTO for U.S. application 09/773,672.
	AL	A "Notice of References Cited" from the USPTO for U.S. application 09/773,675.

Examiner Signature

Date Considered

10-29-04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

* Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

DEC 30 2002 Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PATENTS & TRADEMARKS
SEARCHED
SERIALIZED
INDEXED
FILED
JCS

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

7 of 8

Complete if Known

Application Number	10/086,417
Filing Date	March 4, 2002
First Named Inventor	Bernd Riedl et al.
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	BAYER 16P4

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AM	A "Notice of References Cited" from the USPTO for U.S. application 09/776,835.	
	AN	A "Notice of References Cited" from the USPTO for U.S. application 09/778,936.	
	AO	A "Notice of References Cited" from the USPTO for U.S. application 09/777,920.	
	AP	A "Notice of References Cited" from the USPTO for U.S. application 09/048,915.	
	AQ	A "Notice of References Cited" from the USPTO for U.S. application 10/042,226.	
	AR	A "Notice of References Cited" from the EPO for European application EP 98/963809.	
	AS	Supplemental search report from the EPO for European application EP 98/963810.	
	AT	Supplemental search report from the EPO for European application EP 98/963981.	
	AU	Supplemental search report from the EPO for European application EP 00/903239.	
	BA	International search report for International Application No. PCT/US98/10375.	
	BB	International search report for International Application No. PCT/US98/10376.	

Examiner Signature	<i>CM</i>	Date Considered	10-29-04
--------------------	-----------	-----------------	----------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RJT/lvb

K:\Bayer125\refs cited ids.10-29-02.dot

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

8

of

8

Application Number	10/086,417
Filing Date	March 4, 2002
First Named Inventor	Bernd Riedl et al.
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	BAYER 16P4

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	BC	International search report for International Application No. PCT/US98/26078.	
	BD	International search report for International Application No. PCT/US98/26079.	
	BE	International search report for International Application No. PCT/US98/26080.	
	BF	International search report for International Application No. PCT/US98/26081.	
	BG	International search report for International Application No. PCT/US98/26082.	
	BH	International search report for International Application No. PCT/US98/24285.	
	BI	International search report for International Application No. PCT/US00/00648.	
	BJ	International search report for International Application No. PCT/US00/00768.	
	BK	International search report for International Application No. PCT/US02/12064.	
	BL	International search report for International Application No. PCT/US02/12066.	
	BM	International search report for International Application No. PCT/US/26081.	

Examiner Signature	<i>CM</i>	Date Considered	10-29-04
--------------------	-----------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RJT/lvb

K:\Bayer\25A\refs cited ids 10-29-02.dot